Metformin prevents ischaemic ventricular fibrillation in metabolically normal pigs
Metformin is the drug most often used to treat type 2 diabetes. Evidence suggests that metformin may reduce mortality of individuals with type 2 diabetes, but the mechanism of such an effect is unknown and outcomes of metformin treatment in people without diabetes have not been determined. If metformin favourably affected mortality of non-diabetic individuals, it might have even broader therapeutic utility. We evaluated the effect of metformin on myocardial energetics and ischaemic ventricular fibrillation (VF) in metabolically normal pigs.
Domestic farm pigs were treated with metformin (30 mg kg−1 day−1 orally for 2–3 weeks; n = 36) or received no treatment (n = 37). Under anaesthesia, pigs underwent up to 90 min low-flow regional myocardial ischaemia followed by 45 min of reperfusion. Pigs were monitored for arrhythmia, monophasic action potential morphology, haemodynamics and myocardial substrate utilisation, AMP-activated protein kinase (AMPK) phosphorylation activity and ATP concentration.
Death due to VF occurred in 12% of pigs treated with metformin compared with 50% of untreated controls (p = 0.03). The anti-fibrillatory effect of metformin was associated with attenuation of action potential shortening in ischaemic myocardium (p = 0.02) and attenuation of the difference in action potential duration between ischaemic and non-ischaemic regions (p < 0.001) compared with untreated controls. Metformin had no effect on myocardial contractile function, oxygen consumption, or glucose or lactate utilisation. During ischaemia, however, metformin treatment amplified the activation of AMPK and preserved ATP concentration in myocardium compared with untreated controls (each p < 0.05).
Chronic treatment of metabolically normal pigs with metformin at a clinically relevant dose reduces mortality from ischaemic VF. This protection is associated with preservation of myocardial energetics during ischaemia. Maintenance of myocardial ATP concentration during ischaemia is likely to prevent action potential shortening, heterogeneity of repolarisation, and propensity for lethal arrhythmia. The findings suggest that metformin might be protective in non-diabetic individuals with coronary heart disease.
KeywordsAction potential ATP Ischaemia Metformin Ventricular fibrillation
AMP-activated protein kinase
Left anterior descending coronary artery
Monophasic action potential
- 3.Bannister CA, Holden SE, Jenkins-Jones S et al (2014) Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes Obes Metab 16:1165–1173CrossRefPubMedGoogle Scholar
- 19.Greyson C, Garcia J, Mayr M, Schwartz GG (1995) Effects of inotropic stimulation on energy metabolism and systolic function of ischemic right ventricle. Am J Phys 268:H1821–H1828Google Scholar
- 22.Bethell HW, Vandenberg JI, Smith GA, Grace AA (1998) Changes in ventricular repolarization during acidosis and low-flow ischemia. Am J Phys 275:H551–H561Google Scholar
- 41.VA Office of Research and Development (2016) Investigation of metformin in pre-diabetes on atherosclerotic cardiovascular outcomes (VA-IMPACT). Available from www.clinicaltrials.gov. Accessed 20 Feb 2017
- 42.Cambridge University Hospitals, NHS Foundation Trust, and the University of Cambridge (2014) Glucose lowering in non-diabetic hyperglycaemia trial (GLINT). Available from www.clinicaltrialsregister.eu. Accessed 20 Feb 2017